Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment

Antibiotics need to be effective in diverse environments in vivo. However, the pathogen microenvironment can have a significant impact on antibiotic potency. Further, antibiotics are increasingly used in combinations to combat resistance, yet, the effect of microenvironments on drug-combination efficacy is unknown. To exhaustively explore the impact of diverse microenvironments on drug-combinations, here we develop a computational framework—Metabolism And GENomics-based Tailoring of Antibiotic regimens (MAGENTA). MAGENTA uses chemogenomic profiles of individual drugs and metabolic perturbations to predict synergistic or antagonistic drug-interactions in different microenvironments. We uncovered antibiotic combinations with robust synergy across nine distinct environments against both E. coli and A. baumannii by searching through 2556 drug-combinations of 72 drugs. MAGENTA also accurately predicted the change in efficacy of bacteriostatic and bactericidal drug-combinations during growth in glycerol media, which we confirmed experimentally in both microbes. Our approach identified genes in glycolysis and glyoxylate pathway as top predictors of synergy and antagonism respectively. Our systems approach enables tailoring of antibiotic therapies based on the pathogen microenvironment.

[1]  R. Bonomo,et al.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time? , 2015, Critical care medicine.

[2]  M. Oh,et al.  Gene Expression Profiling by DNA Microarrays and Metabolic Fluxes in Escherichiacoli , 2000, Biotechnology progress.

[3]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[4]  J. Martínez,et al.  Metabolic regulation of antibiotic resistance. , 2011, FEMS microbiology reviews.

[5]  E. Brown,et al.  Unconventional screening approaches for antibiotic discovery , 2015, Annals of the New York Academy of Sciences.

[6]  Ahmad S Khalil,et al.  Antibiotics induce redox-related physiological alterations as part of their lethality. , 2014, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Achim Zeileis,et al.  BMC Bioinformatics BioMed Central Methodology article Conditional variable importance for random forests , 2008 .

[8]  N. Krogan,et al.  Phenotypic Landscape of a Bacterial Cell , 2011, Cell.

[9]  Mike Tyers,et al.  Systematic chemical-genetic and chemical-chemical interaction datasets for prediction of compound synergism , 2016, Scientific Data.

[10]  M. Joly-Guillou,et al.  Clinical impact and pathogenicity of Acinetobacter. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  R. Hancock,et al.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.

[12]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[13]  J. Bartlett,et al.  Erratum: Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America (Clinical Infectious Diseases (March 1, 2006) 42 (657-668)) , 2006 .

[14]  T. Dandekar,et al.  Carbon metabolism of intracellular bacterial pathogens and possible links to virulence , 2010, Nature Reviews Microbiology.

[15]  C. Houssin,et al.  Effect of osmotic pressure on membrane energy-linked functions in Escherichia coli. , 1991, Biochimica et biophysica acta.

[16]  R. F. Middleton,et al.  The fractional inhibitory concentration (FIC) index as a measure of synergy. , 1983, The Journal of antimicrobial chemotherapy.

[17]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[18]  Matthew R. Laird,et al.  OrtholugeDB: a bacterial and archaeal orthology resource for improved comparative genomic analysis , 2012, Nucleic Acids Res..

[19]  E. Jacoby,et al.  Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.

[20]  Murat Cokol,et al.  Diagonal Method to Measure Synergy Among Any Number of Drugs , 2018, Journal of visualized experiments : JoVE.

[21]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .

[22]  Andrea L. Halweg-Edwards,et al.  The Resistome: A Comprehensive Database of Escherichia coli Resistance Phenotypes. , 2016, ACS synthetic biology.

[23]  Yair Benita,et al.  An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies , 2016, Molecular Cancer Therapeutics.

[24]  Jason H. Yang,et al.  Antibiotic efficacy-context matters. , 2017, Current opinion in microbiology.

[25]  Murat Cokol,et al.  Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis , 2017, Science Advances.

[26]  Ahmad S. Khalil,et al.  Antibiotic efficacy is linked to bacterial cellular respiration. , 2015, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Brown,et al.  Antibacterial drug discovery in the resistance era , 2016, Nature.

[28]  C. Nathan,et al.  Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis , 2014, Nature Communications.

[29]  James J. Collins,et al.  Metabolite-Enabled Eradication of Bacterial Persisters by Aminoglycosides , 2011, Nature.

[30]  R. Kishony,et al.  Multidrug evolutionary strategies to reverse antibiotic resistance , 2016, Science.

[31]  Julio Saez-Rodriguez,et al.  Looking beyond the cancer cell for effective drug combinations , 2016, Genome Medicine.

[32]  M. Feldman,et al.  Uncovering the mechanisms of Acinetobacter baumannii virulence , 2017, Nature Reviews Microbiology.

[33]  Eduardo D Sontag,et al.  Mechanism-independent method for predicting response to multidrug combinations in bacteria , 2012, Proceedings of the National Academy of Sciences.

[34]  Chris Sander,et al.  Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells , 2015, eLife.

[35]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[36]  T. Bollenbach,et al.  Systematic discovery of drug interaction mechanisms , 2015, Molecular systems biology.

[37]  Timothy C. Meredith,et al.  On the essentiality of lipopolysaccharide to Gram-negative bacteria. , 2013, Current opinion in microbiology.

[38]  C. Myers,et al.  Unraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics , 2014, Cell.

[39]  James J Collins,et al.  Chemogenomics and orthology‐based design of antibiotic combination therapies , 2016, Molecular systems biology.

[40]  L. Dijkshoorn,et al.  An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii , 2007, Nature Reviews Microbiology.

[41]  S. Loewe.  The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[42]  U. Alon,et al.  Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.

[43]  Jason H. Yang,et al.  Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control. , 2017, Cell chemical biology.

[44]  J. Bartlett,et al.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Lieberman,et al.  Granzyme B Disrupts Central Metabolism and Protein Synthesis in Bacteria to Promote an Immune Cell Death Program , 2017, Cell.

[46]  R. Gonzalez,et al.  Fermentative Utilization of Glycerol by Escherichia coli and Its Implications for the Production of Fuels and Chemicals , 2007, Applied and Environmental Microbiology.

[47]  G. Forrest,et al.  Rifampin Combination Therapy for Nonmycobacterial Infections , 2010, Clinical Microbiology Reviews.

[48]  Jason H. Yang,et al.  Antibiotic-Induced Changes to the Host Metabolic Environment Inhibit Drug Efficacy and Alter Immune Function. , 2017, Cell host & microbe.

[49]  Luke A. Gilbert,et al.  Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.

[50]  R. Busa-Fekete,et al.  Antagonism between Bacteriostatic and Bactericidal Antibiotics Is Prevalent , 2014, Antimicrobial Agents and Chemotherapy.